PharmaMar Initiates a Phase III Registration Trial with Aplidin(R) in Multiple Myeloma Patients
This pivotal, international, multicenter Phase III clinical trial, called ADMYRE, will enrol 300 patients in 60 medical centers across 20 countries (including the U.S., Europe, Asia and South America), with an estimated recruitment period of 24 months. The primary objective of ADMYRE is Progression Free Survival (PFS).
Aplidin(R) is an anti-tumor agent originally isolated from the Mediterranean tunicate Aplidium albicans and currently obtained by chemical synthesis. Aplidin(R) is the second most advanced compound in clinical development at PharmaMar.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.